Lexicon Pharmaceuticals, Inc.
LXRX· Nasdaq
LXRXLexicon Pharmaceuticals, Inc.
Filed Mar 12, 2021 · 10-K · 71 days after period end · 0001062822-21-000013
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2016dderived from reported figures | Q4 2015 |
|---|---|---|---|---|
| Revenue | $23.37M | $8.73M | -$41.83M | $23.04M |
| Net Income | -$5.50M | -$51.14M | -$28.38M | -$32.42M |
| EPS Diluted | — | -$0.48 | — | -$0.31 |
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Mar 12, 2021 · 71 d after period end
